On the stock market since 2018, it operates in the world of health and science. It has 208 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 27% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $8.4M. In times of high interest rates, a gap like that can squeeze a company.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 19% a year on average.
The stock sits at $0.31. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, ROMJF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ROMJF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.